Clinical stage biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) has garnered our attention as the stock touched a 52-week high, with momentum supported by recent clinical updates and an in-person FDA meeting on its U.S. preeclampsia program.
We first profiled DMAC on June 4, 2025, when shares were trading around $4.15. Since then, the stock has climbed steadily, reaching a new 52-week high of $7.68 on Thursday. It closed the regular session at $7.22, down 1.10% or $0.08, before advancing to $7.42 in after-hours trading, a gain of 2.79% or $0.20. Trading volume came in at 517,594 shares, well above the average of 390,382, lifting the company's intraday market capitalization to about $376 million.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.